Viewing nowCombinationDik Double M Tablet 10/4 mg (Dapagliflozin, Glimepiride)
Dapagliflozin Propanediol Hydrate 12.3mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.

MFDS item code 202300716 · Approved 2023.02.28 · Insurance code 622805020
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as a treatment that combines glimepiride and dapagliflozin to improve blood sugar control in patients with type 2 diabetes, helping to complement diet and exercise therapies. Such combination therapy enhances blood sugar control effects, making diabetes management more effective. Patients will find that taking this medication alongside consistent dietary management and regular exercise will significantly aid in blood sugar control.
For patients taking glimepiride 4 mg and dapagliflozin 10 mg, 1 tablet (10mg/4mg of dapagliflozin/glimepiride) may be taken once daily immediately before breakfast or before the first meal. It is very important not to skip a meal after taking this medicine. Patients who require a reduction in the dose of glimepiride should take the individual component preparations. Swallow the tablet whole. While taking this medicine, blood glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. The risk of hypoglycemia may increase during treatment with this medicine. The risk may be greater particularly when accompanied by weight loss, lifestyle changes, and other factors that may increase the risk of fluctuations in blood glucose. Hypoglycemia can generally be promptly controlled by immediate intake of sugar, but it may recur despite successful initial management. Therefore, patients should be carefully monitored while receiving this medicine. Severe hypoglycemia requires immediate medical intervention and follow-up, and hospitalization may sometimes be necessary (see Precautions for Use). Special populations 1) Patients with renal impairment: The efficacy of dapagliflozin, an active ingredient in this medicine, depends on renal function, and patients with impaired renal function may be more sensitive to the glucose-lowering effect of glimepiride. Therefore, assess renal function before starting this medicine and closely monitor renal function and changes in blood glucose after treatment is initiated. This medicine is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73m2, and should not be administered to patients with severe renal impairment or worse (see Precautions for Use, 1. Do not administer to the following patients and 2. Administer with caution to the following patients). 2) Patients with hepatic impairment: Carefully monitor patients with hepatic impairment when initiating this medicine. Do not administer this medicine to patients with severe hepatic impairment (see Precautions for Use, 1. Do not administer to the following patients and Administer with caution to the following patients).
This medication should not be taken by certain patients. Patients with allergies to the main ingredients, excipients, or sulfonylureas should not take this medication. Patients with type 1 diabetes or those who have experienced diabetic ketoacidosis or coma should not use this medication. Additionally, it contains anhydrous lactose, which may pose risks to those with lactose intolerance or certain genetic issues. Patients with severe kidney or liver dysfunction, as well as pregnant or breastfeeding women, should not take this medication. Patients with severe infections or those before and after surgery, as well as those with severe trauma, should avoid use, and those with gastrointestinal disorders should be cautious due to the risk of hypoglycemia. Dialysis patients should also refrain from using this medication. Special caution is required when administering this medication to patients with reduced fluid volume or kidney function impairments. Blood pressure drops or worsening kidney function may occur, so it's essential to carefully monitor fluid status and kidney function before and during administration. For patients with severely compromised kidney function, the blood sugar control effect may be diminished, and its use is not recommended. Furthermore, one of the ingredients in this medication poses a risk of hypoglycemia, so careful monitoring of blood sugar levels is essential at the onset of treatment. Special caution is advised for the elderly, individuals with poor nutritional status or irregular eating habits, those with high alcohol consumption, and patients with impaired kidney or liver function, as they are at higher risk of hypoglycemia. If symptoms of hypoglycemia occur, immediate consultation with healthcare providers is necessary, and dosage adjustments may be required. While taking this medication, urinary and genital infections may occur, so immediate treatment is necessary if infection symptoms appear. Dehydration or hypotension symptoms due to reduced fluid volume may also occur, so any symptoms like dizziness or light-headedness should be reported to healthcare providers. Women who are pregnant or may become pregnant, as well as those who are breastfeeding, should not take this medication, and if pregnancy is confirmed, it should be discontinued immediately. Safety and efficacy for children and adolescents under 18 years have not been established, so use in this population is not advised. In cases of overdose, symptoms such as hypoglycemia or dehydration may appear, and immediate medical attention should be sought. Awareness of hypoglycemia risk during treatment is crucial, especially when driving or operating machinery. The medication should be stored out of reach of children and kept sealed in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is also important to maintain its efficacy by storing it at room temperature, between 1 and 30 degrees Celsius.
Yellow oval film-coated tablets
Box - 28 tablets/box [14 tablets/PTP×2], bottle - 30 tablets/bottle, bottle - 300 tablets/bottle, bottle - 1000 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Propanediol Hydrate 12.3mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
Jinyang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
HyunDae Tech (Co., Ltd.)
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Glimepiride 4mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.